Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Table 1 Dose and mode of administration of the study drugs^a

Study drug	Dose and mode of administration
Capecitabine	1000 mg/m² per os twice daily as combined 150 mg and 500 mg tablets on days 1 to 14 of each 21-day cycle, followed by a 7-day resting period (i.e. off-treatment)
Bevacizumab	15 mg/kg intravenously once every 3 weeks (i.e. 5 mg/kg/week dose equivalent)
Everolimus	10 mg per os once daily of each 21-day cycle
Exemestane	25 mg per os once daily of each 21-day cycle

^aDose and mode of administration of the study drugs were in accordance with current SmPC of respective study drug. Study drugs were available upon prescription by respective treating physician. A cycle was defined as 21 days of study treatment

ISSN: 1471-2407